Clinical Trial Update: Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Itacitinib in combination with Tocilizumab for steroid-refractory acute graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Itacitinib (itacitinib)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Columbia University | Conditions: Steroid Refractory GVHD, Graft Vs Host Disease | Phase 1 | Status: TERMINATED